All In Biotech

NDA 216099 · Handa Therap

Phyrago

Dasatinib · Oral

Orphan

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Dec 5, 2023

Approved uses

2

Original approval plus efficacy supplements

Registered trials

366

28 Phase 3, 24 recruiting

FAERS reports

9,294

8,481 serious, 1,354 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 4, 2026.

1. INDICATIONS AND USAGE PHYRAGO is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. PHYRAGO is indicated for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase. newly diagnosed Ph+ ALL in combination with chemotherapy. PHYRAGO ® is a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. ( 1 , 14 ) adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. ( 1 , 14 ) adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. ( 1 , 14 ) pediatric patients 1 year of age and older with Ph+ CML in chronic phase. ( 1 , 14 ) pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy. ( 1 , 14 )

Mechanism: Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate- sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib could overcome imatinib resistance...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 1, 2025 Supplement 5 · Efficacy OrphanLabelLetter
  • Dec 5, 2023 Original approval · Type 5 - New Formulation or New Manufacturer OrphanLetterLabelReview
6 products under this application
  • PHYRAGO · DASATINIB 100MG · TABLET, ORAL · Prescription
  • PHYRAGO · DASATINIB 70MG · TABLET, ORAL · Prescription
  • PHYRAGO · DASATINIB 20MG · TABLET, ORAL · Prescription
  • PHYRAGO · DASATINIB 140MG · TABLET, ORAL · Prescription
  • PHYRAGO · DASATINIB 80MG · TABLET, ORAL · Prescription
  • PHYRAGO · DASATINIB 50MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Dasatinib" as an intervention, any sponsor and status, largest first.

All 366 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pleural effusion1,211
  • drug ineffective728
  • drug intolerance575
  • drug resistance538
  • death470
  • diarrhoea441
  • thrombocytopenia430
  • dyspnoea416
  • malignant neoplasm progression399
  • fatigue384
  • nausea374
  • pyrexia373

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200640
2007106
2008113
2009162
2010158
201194
2012244
2013221
2014372
2015324
2016428
2017538
2018647
2019767
2020706
20211,046
2022541
2023566
2024797
2025821
2026603

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 351 on PubMed

Sponsor: Handa Therap

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.